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Purpose. To evaluate the epidemiology, prognosis, and management of septic shock patients hospitalized in our intensive care unit
(ICU). Materiel and Methods. Five-year monocenter observational study including 320 patients. Results. ICU mortality was 54.4%.
Independent mortality risk factors were mechanical ventilation (OR = 4.97), Simplify Acute Physiology Score (SAPS) II > 60
(OR = 4.28), chronic alcoholism (OR = 3.38), age >65 years (OR = 2.65), prothrombin ratio <40% (OR = 2.37), and PaO2/FiO2
ratio <150 (OR = 1.91). These six mortality risk factors recovered allow screening immediately septic shock patients with a high
mortality risk. Morbidity improved with time (diminution of septic shock complications, increase of the number of days alive free
from mechanical ventilation and vasopressors on day 28), concomitant to an evolution of the management (earlier institution of
all replacement and medical therapies and more initial volume expansion). There was no diﬀerence in mortality. Conclusion.O u r
study conﬁrms a high mortality rate in septic shock patients despite a new approach of treatment.
1.Introduction
A better pathophysiologic knowledge and the apparition of
international recommendations allowed an improvement of
septic shock’s prognosis, but mortality still remains above
50% [1, 2]. Numerous factors are associated to mortality in
septic shock. Early recognition of these factors can help to
identify the most critical situations and to provoke a more
aggressive resuscitation. We realized an observational study
including all the patients suﬀering from septic shock and
hospitalized in our intensive care unit (ICU) from 2003
to 2007. Beyond an epidemiologic analysis, we wanted to
identify mortality risk factors and evolution of septic shock
management in our ICU.
2.MaterialandMethods
2.1. Inclusion Criteria and Study Aims. We included all the
patients suﬀering from septic shock and hospitalized in the
ICU of Tourcoing hospital, France, between January 2003
and January 2008. Our study had 3 aims: an epidemiologic
record, the identiﬁcation of independent mortality risk
factors, and the evaluation of management and prognosis
comparing 2 periods, before and after the publication of the
Surviving Sepsis Campaign (SSC) international guidelines in
December 2004 [3].
2.2. Data Collection and Deﬁnitions
2.2.1. On Admission. For all patients, the following char-
acteristics were prospectively collected on ICU admission:
age,gender,underlyingclinicalconditions,severityofillness,
and vital sign abnormalities. Severity of illness was assessed
by the Simpliﬁed Acute Physiology Score (SAPS) II [4]a n d
the Sepsis-related Organ Failure Assessment (SOFA) score
[5]. We estimated an organ dysfunction if the score for
this organ was superior to 3. Septic shock was deﬁned as
a sustained (≥1h) decrease in the systolic blood pressure
of at least 40mmHg from baseline or a resultant systolic
blood pressure <90mmHg after adequate ﬂuid replacement2 Critical Care Research and Practice
and in the absence of any antihypertensive drug [6]. We
recorded the community or hospital-acquired origin of the
infection, bacteriological data and if the patient presented
coinfection (more than one pathologic bacteria recovered).
We also noted the delay from the hospital admission, from
the onset of the sepsis and the septic shock, to the admission
in the ICU. We recorded all the bacteriological samples as
well as the initial antibiotic therapy. Antibiotic therapy was
deﬁned as adapted (if it followed recommendations), and
adequate (if it comported at least one antibiotic active in
vitro on the causal bacteria). Delay from the onset of the
sepsis to the start of the antibiotic treatment was also noted.
Volume expansion with hydroxyethylstarches (HES),
cristalloids, 4% albumin and packed red blood cells was
quantiﬁed at 6 and 24 hours after the onset of the sepsis as
well as vasopressor use. We also recorded the use of activated
protein C, hydrocortisone, intensive insulin therapy, type
and amount of nutrition, need for mechanical ventilation
or renal replacement therapy (RRT). We also noted the time
from the beginning of vasopressors and the prescription of
hydrocortisone, nutrition, ventilation, and RRT.
2.2.2. Evolution. We recorded if the patients presented a
recurrenceofshock(needforvasopressorafter8hourswean-
ing). During the ICU stay, occurrence of complications was
recorded. We distinguished infection-related complications
(acute respiratory distress syndrome (ARDS), acute renal
failure, disseminated intravascular coagulation, and acute
hepatic failure) and hospital-acquired infections. Finally, we
recorded the number of days alive free from mechanical
ventilation, vasopressors, and RRT on day 28. Mortality was
evaluated on day 28 and at ICU discharge.
2.3. Statistical Analysis. To determine the factors associated
withmortality,werealizedalogisticregressionanalysis.First,
we performed a monovariate analysis, and then pooled the
signiﬁcant parameters (P<. 2) in a multivariate analysis
with the estimate of the Odds Ratio (OR). For multivariate
analysis, an area under the curve was used to determine
the cut-oﬀ of continuous variables. Comparisons between
groups were performed using Chi-square test or Fisher’s
exact test for categorical parameters. Continuous variables
were analysed using Wilcoxon’s test. Diﬀerences between
groups were considered to be signiﬁcant for variables
yielding a P value <. 05. All analyses were performed using
the SAS Software, V8.2.
3. Results
3.1. Baseline Characteristics on Admission. Between January
2003 and January 2008, 320 patients were hospitalized in our
ICU for septic shock. Sixty three percent of the population
was male, mean age was 65 ± 15.3y e a r s ,S A P SI Ia n d
S O F As c o r ew e r e6 2 .3 ± 20.1a n d1 1 .3 ± 3.2, respectively.
The major comorbidity was chronic alcoholism (26.8%),
followed by chronic obstructive pulmonary disease (COPD
(25.2%)), diabete mellitus (21.8%), and chronic cardiac
failure (18%). Associated organ failures were respiratory
(83.6%), neurologic (35.7%), renal (26.3%), coagulation
(15.2%), and hepatic (3.5%). Mean times from the hospital
admission,theonsetofthesepsisandthesepticshocktoICU
admissionwere3.8±7.5da y s,16.7±28.8hours,and2.4±4.8
hours, respectively.
3.2. Bacteriology and Antibiotic Therapy. The sepsis was
community-acquired in 64% of the patients. Infectious
site was predominantly respiratory (48.4%), followed by
intraabdominal (20%) and urinary (8.7%). The infec-
tion was bacteriologically documented in 59% of the
patients, with 33% of positive blood cultures. 20.4% of
the patients presented coinfections. Causative pathogens
were Gram-positive cocci in 45.3% of the positive cultures,
mostly represented by Streptococcus pneumoniae (17.4%)
and Staphylococcus aureus methicillin-sensitive (11.6%),
and methicillin-resistant (4.2%). Gram-negative bacilli were
found in 43.2%: Escherichia coli (15.8%), Klebsiella (5.3%),
and Pseudomonas aeruginosa ticarcillin-sensitive (4.7%) and
ticarcillin-resistant (3.7%). Anaerobes bacteria represented
3.7% and Candida 2.6% of the cases. Mean time from the
onset of the sepsis to the introduction of antibiotics was
9.8±18.7 hours. It was adapted in 97% and adequate in 88%
of the patients.
3.3. Management. Mean plasma volume expansion during
the 24 hours following the sepsis was 1160 ± 793mL for
HES and 2194 ± 1720mL for cristalloids. The most used
vasopressor agent was norepinephrine in 74%, followed
by dopamine (42%), dobutamine (26%), and epinephrine
(16%). Only 7% of the patients received activated protein
C. Hydrocortisone was prescribed in 84% of the population,
7.9±12hoursaftertheonsetofshock.Mechanicalventilation
was needed in 88%; noninvasive ventilation was performed
in 13% of the patients. Thirty one percent of the patients
needed RRT.
3.4. Prognosis on Day 28. Recurrence of shock was noted
in 24% of the population, complications of septic shock in
28.2% and hospital-acquired infections in 25.7% with 32%
of multiresistant bacteria. ICU mortality was 54.4%, day
28 mortality 51.2%. Time alive free from ICU, mechanical
ventilation, vasopressors, and RRT on day 28 was 5.6 ± 8.8
days, 5.3 ± 8.4d a y s ,1 0 .1 ± 10.5d a y sa n d9± 11.2d a y s ,
respectively.
3.5. Independent Mortality Risk Factors. For all the collected
variables, we realized a bivariate analysis (Table 1), and then
all the signiﬁcant parameters were entered in a multivariate
analysis. We found 6 independent variables associated with
mortality: need for mechanical ventilation, SAPS II >60,
chronic alcoholism, age >65 years, prothrombin ratio (PR)
<40% and PaO2/FiO2 <150 (Table 2).
3.6. Comparison of the 2003-2004 and 2005–2007 Periods.
The 2003-2004 period represented 41.9% of the population.
The 2 groups were homogeneous for baseline characteristics
except more chronic cardiac failures (27.8% versus 10.8%,Critical Care Research and Practice 3
Table 1: Mortality risk factors in septic shock patients: monovariate analysis COPD: chronic obstructive pulmonary disease, SAPS: simplify
acute physiology score, SOFA: sepsis-related organ failure assessment score, ICU: intensive care unit, RRT: renal replacement therapy,
prothrombin ratio (PR).
Survivors 146 (45.6) Deceased174 (54.4) P
Comorbidities n(%)
Chronic cardiac failure 21(14.4) 36(21) .1233
Diabete mellitus 29(19.9) 40(23.4) .4479
COPD 35(23.9) 45(26.3) .6321
Chronic liver failure 11(7.5) 24(14) .0656
Chronic alcoolism 28(19.1) 57(33.3) .0046
Chronic renal failure 6(4.1) 10(5.8) .4810
Non hematologic malignancy 16(10.9) 20(11.6) .8367
Hematologic malignancy 16(10.9) 16(9.3) .6369
Immunosuppression 25(17.1) 24(14) .4484
Clinical presentation
Male sex n(%) 92(63) 111(63.8) .8853
Age (years) (mean ± SD) 61.6 ±15.56 8 .5 ±14.3 <.0001
Lactate (meq/l) (mean ± SD) 3 ± 2.24 .9 ±4 <.0001
Platelet count (1000/mm3) (mean ± SD) 203 ±144 198 ±143 .7813
Creatinine (mg/l) (mean ± SD) 21.6 ±15.42 2 .7 ±12.3 .4825
Bilirubine (mg/l) (mean ± SD) 14.2 ±13.52 0 .6 ±27.4 .0157
PR (%) (mean ± SD) 58.6 ±19.84 9 .6 ±20.5 <.0001
pH (mean ± SD) 7.3 ±0.17 .2 ±0.1 .0007
PaO2/FiO2 (mean ± SD) 190 ±103 154 ±101 .0021
SAPS II (mean ± SD) 52.7 ±13.97 0 .3 ±20.9 <.0001
SOFA score (mean ± SD) 10.6 ±31 1 .9 ±3.1 .0002
Respiratory failure n(%) 123(84.2) 153(88.4) .2746
Renal failure n(%) 30(20.5) 53(31.1) .0323
Coagulation failure n(%) 21(14.3) 29(17.2) .4869
Hepatic failure n(%) 1(0.7) 10(6) .0108
Neurologic failure n(%) 40(28.5) 70(41.6) .0169
Management
Time from shock to ICU admission (hours) (mean ± SD) 2.5 ±5.62 .2 ±4 .6034
Adapted antibiotic therapy n(%) (mean ± SD) 138(97.8) 154(96.8) .7269
Time from sepsis to adapted antibiotic therapy (hours) (mean ± SD) 8 ±18.21 1 .2 ±19 .1426
Adequate antibiotic therapy n(%) 89(92.7) 76(83.5) .0512
Time from sepsis to adequate antibiotic therapy (hours) (mean ± SD) 10.3 ±23.31 5 .4 ±25.7 .1698
Mechanical ventilation n(%) 116(79.4) 166(95.9) <.0001
Noninvasive ventilation n(%) 12(8.6) 27(15.6) .0614
Time from shock to intubation (hours) (mean ± SD) 2.5 ±6.43 .3 ±9.8 .4050
RRT n(%) 41(28) 57(33.1) .3304
Time from shock to RRT (hours) (mean±SD) 29 ± 38.72 9 .7 ±33.4 .9216
Cristalloid volume expansion at 6 hours of sepsis (mL) (mean ± SD) 1302 ±1123 974 ±1127 .0135
Cristalloid volume expansion at 24 hours of sepsis (mL) (mean ± SD) 2629 ±1748 1842 ±1618 <.0001
Hydrocortisone n(%) 123(84.2) 147(84.4) .9538
Time from shock to initiation of hydrocortisone (hours) (mean ± SD) 8.2 ±13 7.4 ±10.9 .5985
Activated proteine C n(%) 13(8.9) 8(4.6) .1246
Intensive insulin therapy n(%) 94(64.3) 86(49.4) .0072
Enteral nutrition n(%) 101(70.6) 67(51.1) .0009
Parenteral nutrition n(%) 39(27.2) 29(22.1) .3256
Time from shock to initiation of nutrition (days) (mean ± SD) 2.5 ±1.32 .4 ±1.1 .79184 Critical Care Research and Practice
Table 2: Independent mortality risk factors in septic shock patients: multivariate analysis SAPS: simplify acute physiology score,
prothrombin ratio (PR).
Odds ratio Conﬁdence interval P
Mechanical ventilation 4.97 [1.79–13.75] .0021
SAPS II >60 4.28 [2.51–7.13] .0001
Chronic alcoholism 3.38 [1.75–6.52] .0003
Age >65 years 2.65 [1.47–4.79] .0012
PR <40% 2.37 [1.26–4.45] .0074
PaO2/FiO2 <150 1.91 [1.15–3.26] .00183
P = .001) and a lower SOFA score (10.9 ± 3.2v e r s u s1 1 .6 ±
3.2, P = .0338) during the 2003-2004 period. In contrast,
the management of the 2 groups was very diﬀerent: in the
second period, norepinephrine became the vasoactive agent
of choice (P<. 0001) instead of dopamine and dobutamine,
initial plasma volume expansion was greater (P = .0005),
patients received more intensive insulin therapy (P<. 0001),
and the delays of intubation (P = .01), antibiotic therapy
(P = .0037), initiation of hydrocortisone (P = .0001), RRT
(P = .002), and nutrition (P = .0389) were shortened
(Table 3).
Prognosis variables were also diﬀerent between the 2
periods. We found during the period 2005–2007 an increase
in the number of days alive free from mechanical ventilation
(P = .0207) and vasopressors (P = .0021) on day 28,
and a decrease in septic shock complications (P<. 0001).
However, there was no diﬀerence in mortality (P = .79).
All the signiﬁcant diﬀerences concerning the prognosis are
presented Table 4.
4. Discussion
4.1. Epidemiology and Prognosis. Mean age was 65 years
and there was a predominance of male. Three French
epidemiologic studies found a similar repartition [1, 2, 7].
In contrast, our population was particularly severely ill;
mean SAPS II and SOFA scores on admission were 62 and
11, respectively, compared to 58 and 9 in these studies
[1, 2]. The infection was bacteriologically proven in 59%
of the patients, as in the other studies [2, 8, 9]. Literature
data also reveal a change in the origin of the sepsis with
a decrease of intraabdominal and Gram-negative bacilli
infections replaced by pulmonary and Gram-positive cocci
infections [10–12]. It is in accordance with our results: half
of the infections was coming from the respiratory tract
and was caused by Gram-positive cocci. Annane, realizing a
multicenterepidemiologicstudybetween1993to2000found
a 60.1% mortality rate, with an improvement from 1993
(62.1%) to 2000 (55.6%) [2]. This improvement seems to be
relatedtoanearlierandmoreaggressivemanagementandan
improvement in speciﬁc anti-infectious therapies [13–15].
ICU mortality in our study was 54.4%. Most other published
studies found a 35% mortality rate, but patients with severe
sepsis were also included [1, 10, 16–18].
We recovered six independent mortality risk factors:
mechanical ventilation, SAPS II >60, chronic alcoholism,
age >65 years, PR <40%, and PaO2/FiO2 ratio <150. These
factors can easily be available on admission and allow
screening immediately a group of patients with a high
mortality risk. Our results conﬁrm the classic risk factors
associated with mortality recovered in the literature [1, 2,
7, 10]. Speciﬁcally regarding chronic alcoholism, numerous
studies report its association with the frequency of infections
[19, 20], but an important role in mortality in the absence
of hepatic failure is not well known, excepted in the study
by O’Brien [21] who found an increase in mortality in ICU
patients suﬀering from chronic alcoholism, and particularly
when patients developed severe sepsis and septic shock.
Its deleterious eﬀect was probably revealed by the high
prevalence of alcoholism in our population (26.8%).
Most shocking is the absenceof signiﬁcation of antibiotic
therapy.Numerousstudies[9,22,23]showedanimpairment
of the prognosis when antibiotic therapy was delayed. In
particular, Kumar found a 7.6% increased mortality for each
hour delay of antibiotics [24]. Mean time for antibiotic
therapy in our study was very long (9.77 hours), but it
was calculated from the onset of the sepsis and not septic
shock.Adequateantibiotictherapyimprovestheprognosisof
patients suﬀering from septic shock. In our study, antibiotic
therapy was adapted in 97% of the patients and adequate
in 88%. These results are excellent, compared, for example,
to a 2003 american study who found 23% of nonadapted
antibiotictherapy,responsibleofanincreaseinmortality[9].
Theseimportantpercentagesprobablyexplaintheabsenceof
signiﬁcation of antibiotics in our study.
4.2. Comparison of 2003-2004 and 2005–2007 Periods. In
spite of a higher SOFA score during the 2005–2007
period, the mortality remained the same but some vari-
ables improved (diminution of septic shock complications,
increase of the number of days alive free from mechanical
ventilation and vasopressors on day 28). We tried to ﬁnd
if the evolution in the management of our patients could
explain these diﬀerences. The ﬁrst hours are critical in
septic shock and the major diﬀerence in the management
betweenthe2periodswastherapiditytoinstituteallmedical
or replacement therapies. Likewise, initial plasma volume
expansion was greater in the last period. Nevertheless,
these volumes of ﬂuids (about 3.5 litres in 24 hours) are
far below others studies where patients received nearly
5 or 6 litres [1, 3, 7, 11, 12, 14, 23]. The aggressive
   early goal directed therapy    [14] is recommended byCritical Care Research and Practice 5
Table 3: Baseline characteristics and management of septic shock patients: signiﬁcant diﬀerences between the 2003-2004 and 2005–2007
periods.COPD:chronicobstructivepulmonarydisease,SAPS:simplifyacutephysiologyscore,SOFA:sepsis-relatedorganfailureassessment
score, ICU: intensive care unit, RRT: renal replacement therapy, prothrombin ratio (PR).
2003-2004 2005–2007 P
Comorbidities n(%)
Chronic cardiac failure 37(27.8) 20(10.8) .001
Diabete mellitus 34(25.6) 35(19) .16
COPD 39(29.3) 41(22.3) .1544
Chronic liver failure 19(14.3) 16(8.7) .1171
Chronic alcoolism (24.8) (28.3) .4939
Chronic renal failure 8(6) 8(4.3) .5034
Non hematologic malignancy 8(6) 28(15.2) .8367
Hematologic malignancy 18(13.5) 14(7.6) .084
Immunosuppression 18(13.5) 31(16.8) .4205
Clinical presentation
Male sex n(%) 82(61.2) 121(65) .4794
Age (years) (mean ± SD) 63.9 ±15.26 6 .5 ±15.3 .1374
Lactate (meq/l) (mean ± SD) 4.6 ±4.13 .7 ±2.9 .0993
Platelet count (1000/mm3) (mean ± SD) 180 ±1410 215 ±144 .0345
Creatinine (mg/l) (mean ± SD) 22.4 ±14.62 2 .1 ±13.3 .8113
Bilirubine (mg/l) (mean ± SD) 20.8 ±21.11 5 .4 ±22.4 .0425
PR (%) (mean ± SD) 52.1 ±21.55 5 .1 ±20.1 .2117
pH (mean ± SD) 7.29 ±0.14 7.29 ±0.13 .7409
PaO2/FiO2 (mean ± SD) 161.1 ±96.4 177.9 ±107.9 .1649
SAPS II (mean ± SD) 60.8 ±20.16 3 .4 ±20.1 .259
SOFA score (mean ± SD) 10.9 ±3.21 1 .6 ±3.2 .0338
Management
Mechanical ventilation n(%) (85.1) (90.8) .1143
Norepinephrine n(%) 79(59) 158(85.4) <.0001
Dobutamine n(%) 51(38.1) 32(17.4) <.0001
Dopamine n(%) 91(67.9) 43(23.4) <.001
Intensive insulin therapy n(%) 17(12.7) 163(87.6) <.0001
Time from sepsis to adapted antibiotic treatment (hours) (mean ± SD) 13.9 ±18.77 .2 ±18.3 .0037
Cristalloid volume expansion at 6 hours of sepsis (mean ± SD) 816 ±1038 1323 ±1155 .0001
Cristalloid volume expansion at 24 hours of sepsis (mean ± SD) 1773 ±1674 2479 ±1696 .0005
Time from shock to initiation of hydrocortisone (hours) (mean ± SD) 11.3 ±14 5.6 ±9.8 .0001
Time from shock to intubation (hours) (mean ± SD) 4.6 ±11.91 .9 ±5.2 .0105
Time from shock to RRT (hours) (mean ± SD) 43.6 ±42 20.8 ±28.1 .002
Time from shock to initiation of nutrition (days) (mean ± SD) 2.7 ±1.42 .3 ±1.1 .0389
Table 4: Prognosis of septic shock patients: comparison between the 2003-2004 and 2005–2007 periods. ICU: intensive care unit, RRT: renal
replacement therapy.
2003-2004 2005–2007 P
Septic shock complications n(%) 60(46.5) 29(15.6) <.0001
Number of days alive free from mechanical ventilation on day 28 (mean ± SD) 3.9 ±6.96 .2 ±9.1 .0207
Number of days alive free from vasopressors on day 28 (mean ± SD) 8 ±9.61 1 .6 ±10.9 .0021
Number of days alive free from RRT on day 28 (mean ± SD) 8.6 ±12.19 .2 ±10.7. 7 6
Patients discharged from ICU on day 28 n(%) 46(34.6) 69(37.1) .6452
ICU death n(%) 74(55.2) 100(53.8) .79586 Critical Care Research and Practice
the SSC [3], because of its beneﬁcial eﬀect on mortality. Even
with an increase in plasma volume expansion between the 2
periods, it remains probably too low. This is well explained
by the diﬃculty to translate prospective controlled studies in
daily clinical practice. Moreover, we collected the data from
the onset of the sepsis when patients were often hospitalized
in other units and physicians who are not intensivists are
not sensitized to the importance of an aggressive volume
expansion.
Regarding the hemodynamic support, norepinephrine
became the vasopressor of choice in replacement of
dopamine. Likewise, the dobutamine was used very often
before 2005 and its indication was restricted after. This
is conforming to the recommendations of the SSC [3].
Activated protein C is a controversial treatment of septic
shock and is not a high grade recommendation in the 2008
SSC [25]. Waiting for the results of ongoing studies, we
do not often use this molecule (4.5% and 8.1% of the
patients during the 2 periods), so we cannot evaluate it in
our study. Hydrocortisone was largely used during the 2
periods(80.6%and87.1%),followingthestudypublishedby
Annane in 2002 [26]. Finally, the 2004 recommendations [3]
have contributed to introduce more intensive insulin therapy
in our ICU. Van den Berghe et al. [27] have demonstrated
in 2001 a reduction of mortality in surgical patients when
maintaining glycaemia between 0.8 to 1.1g/l with a decrease
in multiorgan failures secondary to septic shock. The same
team [28] did not conﬁrm their results in a population of
medical patients and the study recently published by Arabi
do not support this intensive strategy [29]. In our study,
we did not ﬁnd deleterious eﬀect of insulin, but we did not
recorded hypoglycaemia.
5. Conclusion
The six mortality risk factors recovered in the multivariate
analysis can easily be available on admission and allow
screening immediately a group of patients with a high
mortality risk. Concerning the evolution of the management
during these 5 years, even if it is diﬃcult in usual practice
to be completely in accordance with recommendations, we
remark an earlier introduction of numerous replacement
and medical therapies as well as a more initial aggressive
volume expansion. This probably explains the improvement
in morbidity, whereas mortality did not change.
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